Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy

Related Experiment Video

Updated: Jul 5, 2026

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Tal I Arnon1, Gal Markel, Ahuva Bar-Ilan

  • 1Division of Biology, California Institute of Technology, Pasadena, California, United States of America.

Plos One
|May 15, 2008
PubMed

Insights

Natural cytotoxic receptors (NCRs) like NKp30-Ig show promise as novel anti-tumor agents, inhibiting prostate cancer growth and aiding in differentiating benign from malignant conditions.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Natural cytotoxic receptors (NCRs) are activating proteins on natural killer (NK) cells crucial for anti-tumor immunity.
  • NCRs, including NKp46, NKp44, and NKp30, target various tumor cells, suggesting therapeutic potential.
  • Tumor ligands for NCRs remain unidentified, yet their selective targeting offers a basis for novel cancer therapies.

Purpose of the Study:

  • To investigate the therapeutic potential of NCRs as anti-tumor agents.
  • To evaluate the efficacy of soluble NCR-Ig fusion proteins in inhibiting tumor growth.
  • To explore the diagnostic capabilities of NCR-Ig fusion proteins in distinguishing prostate cancer from benign conditions.

Main Methods:

  • Generation of soluble NCR-Ig fusion proteins by fusing the extracellular portion of NCRs to human IgG1.
  • In vivo testing of NKp30-Ig efficacy against human prostate cancer cell lines.
  • Assessment of antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by activated macrophages.
  • Evaluation of Ig fusion proteins' ability to differentiate between prostate cancer and benign prostate hyperplasia.

Main Results:

  • NKp30-Ig treatment significantly inhibited tumor growth in vivo in human prostate cancer models.
  • Activated macrophages induced ADCC against prostate cancer cells coated with NKp30-Ig.
  • The Ig fusion proteins demonstrated the ability to distinguish between benign prostate hyperplasia and prostate cancer.

Conclusions:

  • Soluble NKp30-Ig fusion proteins represent a promising therapeutic strategy for prostate cancer.
  • NCR-Ig fusion proteins can elicit anti-tumor immune responses, including ADCC.
  • NCR-Ig fusion proteins may offer a novel diagnostic tool for differentiating prostate pathologies.

More Related Videos

Natural Killer (NK) and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line11:02

Natural Killer (NK) and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins07:20

Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins

Published on: June 14, 2018

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cells of the Innate Immune Response01:28

Cells of the Innate Immune Response

The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
Immune Surveillance by NK Cells and Phagocytes01:25

Immune Surveillance by NK Cells and Phagocytes

Immune surveillance is an integral part of the innate immune system, involving the continuous monitoring of peripheral tissues to detect and respond to pathogens, infected cells, or cancerous cells. This surveillance is conducted primarily by natural killer (NK) cells and phagocytes, which employ distinct but complementary mechanisms to identify and eliminate threats.
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...